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Infantile capillary hemangiomas (IHs) are common, benign, high ﬂow, vascular tumors affecting children.
These lesions typically involute spontaneously leaving no long-term sequelae and require no treatment.
IHs can, however, be life and vision threatening depending on their extent and location. These lesions can
be addressed with a number of treatment options including corticosteroids, surgical excision, and laser.
Most recently, b-blockers have shown promising results when used both systemically and topically to
treat IH. Beta-blockers are an exciting new treatment option for IH and have shown promising results
with few reported side effects.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Infantile capillary hemangiomas (IHs) are common, benign, self-
limited tumors1 with a well-deﬁned natural history occurring most
often on the head and neck. This article discusses IH, which is a
distinct tumor from congenital hemangiomas. Congenital heman-
giomas, unlike IHs, are present at birth and do not proliferate. IHs
are the most common soft-tissue tumors in infancy and occur in 5e
10% of children.2e7 Risk factors identiﬁed for IH include female sex,
low birth weight, Caucasian ethnicity, and infants who are products
of multiple gestation pregnancies.2,3,8 Previously believed to be
sporadic, recent studies have suggested IHs may have a familial
association. The Hemangioma Investigator Group reported that 32%
of patients with IH had a ﬁrst-degree relative with a vascular
anomaly. Walter et al found a linkage to chromosome 5q31e33 in
ﬁve families with hemangiomas and vascular tumors.4,8,9 The
pathogenesis of IH is poorly understood and the decision to treat as
well as the treatment modalities vary depending on the extent and
location of the lesion.
These tumors are typically noted in the ﬁrst few days of life and
grow over 6e12 months prior to stabilization and subsequent
spontaneous involution. It has been reported that resolution occurs
in 49% of patients by age 5 years and in 72% of patients by age 7
years.10 The precise mechanisms controlling this proliferation andFeinberg School of Medicine,
rn.edu (C.B. Chambers).
e Ophthalmologic Society of Taiwinvolution is not clearly understood; however, angiogenic markers
such as basic ﬁbroblast growth factor and vascular endothelial
growth factor (VEGF) have been identiﬁed.112. Classiﬁcation
There are many classiﬁcation schemes used for capillary hem-
angiomas. IHs are classiﬁed by the Rootman classiﬁcation system,
which considers pathologic and hemodynamic features of vascular
lesions as new growths in that they are not present at birth, have
endothelial cell proliferation, and are well circumscribed.12 The
Orbital Society Classiﬁcation, which bases classiﬁcation on hemo-
dynamics categorizes IHs as a high ﬂow lesion, derived from mul-
tiple feeder vessels.
In addition to classiﬁcation schemes that use pathology and
blood ﬂow, there are classiﬁcation systems based on location and
morphology. These classiﬁcation schemes are more commonly
used clinically and can provide an insight into the lesions course,
morbidity, and associated sequelae.
IHs are often classiﬁed by their depth: superﬁcial, mixed, and
deep. Superﬁcial hemangiomas are located in the superﬁcial dermis
and look bright red. Deep IHs involve the deep dermis as well as the
subcuticular layer and take on a bluish hue. Mixed hemangiomas
have characteristics of both the superﬁcial and deep variants.8 Deep
and combined hemangiomas have a tendency to have a more
prolonged growth phase than their more superﬁcial counterparts.13
A classiﬁcation based on morphology of the IH can help predict
the need for treatment and comorbidities. This system designatesan. Published by Elsevier Taiwan LLC. All rights reserved.
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angiomas are round discrete lesions where segmental hemangi-
omas involve a broad anatomic region. Segmental hemangiomas
are associated with a higher risk of complications and associated
anomalies such as posterior fossa malformationsehemangiomase
arterial anomaliesecardiac defectseeye abnormalitiesesternal
cleft and supraumbilical raphe syndrome (PHACES).The segmental
lesions are typically larger than localized hemangiomas.15
3. Complications
Most IHs do not require treatment and, after counseling the
family, may be monitored for spontaneous resolution; however,
there are many permanent and life-threatening complications
associated with some IHs.2 The lesion’s location, size, and subtype
can be used to evaluate risk. For every 10 cm2 increase in size, there
is a 4% increase in the need for treatment and a 5% increase in the
rate of complication.16 Segmental hemangiomas also increase the
complication rate and the need to treat independent of size
increase.
When located in the periorbital area, these tumors can be
associated with substantial morbidity as they can cause amblyopia
in up to 60% of children.12,17,18 Amblyopia can be caused by a
number of factors including induced astigmatism, anisometropia,
deprivation amblyopia from mechanical ptosis, or strabismic
amblyopia. Haik et al19 reported that 63% of children with peri-
ocular hemangiomas have a visual acuity difference greater than
two lines between the involved and uninvolved eyes after 5 years’
follow-up. Strabismus is seen in around one-third of patients with
vertical deviations and esotropias being the most common.13,20
Large, deep orbital lesions can also cause dystopia, proptosis,
nerve compromise, and permanent orbital bony deformity sec-
ondary to the mass effect.
Patients with multiple cutaneous IHs are at an increased risk of
visceral hemangiomas. It has been reported that infants with more
than ﬁve cutaneous hemangiomas are at an increased risk of he-
patic involvement.21 Visceral hemangiomas have a higher
morbidity and mortality such as high output heart failure rate than
isolated cutaneous hemangiomas and, therefore, demand careful
monitoring.
Other serious complications from IH include KasabacheMerritt
syndrome, a consumptive coagulopathy, causing hemolytic anemia,
thrombocytopenia, and coagulopathy. This is caused by large, deep
tumors that typically proliferate over a 2e5-year period.22e24 IH
located in the oropharynx or perioral area can cause breathing and
feeding difﬁculties and should be addressed appropriately. PHACES
syndrome should also be evaluated because of the possible sys-
temic morbidities.25e27 Patients with segmental facial hemangi-
omas, not following the ﬁfth cranial nerve pattern, should be
suspect for PHACES.
In addition to the life-and vision-threatening complications,
capillary hemangiomas also have a number of sequelae that should
be considered. Ulceration of the skin overlying the hemangiomas
can lead to bleeding, infection, and scarring. This ulceration typi-
cally occurs in deep hemangiomas secondary to necrosis overlying
the lesion. Other surface abnormalities such as “cigarette paper
skin” or thinned telangiectatic-pigmented skin can be a permanent
disﬁguring lesion left after resolution of superﬁcial capillary
hemangiomas.
4. Traditional treatment options
There are many treatment options for IH each with their own
limitations and side effects. The traditional treatment options
include corticosteroids systemically, by local injection and bytopical application. Vincristine has been used as well as interferon,
laser, and surgical resection. There are few prospective studies
investigating the safety and efﬁcacy of treatment for IH and there
are no US Food and Drug Administration (FDA) approved
treatments.
4.1. Corticosteroids
Corticosteroids have been, for years, considered the primary
treatment option. The exact mechanism of action is unknown;
however, it has been shown in murine models that corticosteroids
disrupt vasculogenesis in stem cells from IH. Corticosteroids also
inhibit VEGF-A expression and silence VEGF-A inhibiting
vasculogenesis.21
Treatment with systemic corticosteroids has shown variable
response with around one-third of the treated lesions regressing,
one-third remaining stable, and one-third demonstrating minimal
response.28 The dosing is variable but typically prednisone is dosed
at 2e3 mg/kg/day by mouth. Side effects of corticosteroids have
been well documented and include ulcers, insomnia, Cushingoid
facies, adrenal suppression, growth retardation, diabetes, and
ulcers.
Intralesional and topical corticosteroids have also been shown
to be effective in the treatment of IH. The response to systemic
corticosteroids and intralesional injection has been reported to be
around the same. The dose of intralesional triamcinolone should
not exceed 3e5 mg/kg per treatment and multiple injections are
often needed. IHs are high-ﬂow lesions; therefore, it is likely that
there is systemic uptake of the medication and therefore a similar
side effect proﬁle as corticosteroids administered systemically can
be demonstrated. In addition, reports of central retinal artery oc-
clusion have been reported. It is hypothesized that, following in-
jection the particles travel in a retrograde direction to enter the
central retinal artery. With local injection of corticosteroids skin
atrophy, necrosis, calciﬁcation, and skin depigmentation can occur.
4.2. Vincristine
Vincristine is less commonly used because it requires the
placement of an access line and can cause neuromyopathy. It is
dosed weekly at 1e1.5 mg/m2. It is historically reserved that IH is
resistant to corticosteroids.
4.3. Interferon
Interferon-a inhibits angiogenesis and is dosed with subcu-
taneous injection of 3 million units/m2/day and has been show to
be effective in the treatment of IH. This treatment is associatedwith
side effects such as fever, neutropenia, and spastic diplegia. Due to
its serious side effects, this treatment option is rarely used.
4.4. Laser
Numerous laser treatments have been used for the treatment of
IH including the pulsed dye laser, carbon dioxide laser, and the
neodymium:yttrium-aluminum-garnet (Nd:YAG) laser. Laser
treatment is most effective when the lesion is ﬂat during the early
proliferative phase. Lasers are limited by the depth of penetration
and may cause ulceration and scarring.
4.5. Surgery
Complete surgical excision of IH is difﬁcult and is most suc-
cessful with well-circumscribed lesions. Surgery is typically per-
formedwhen the lesion is not responsive tomedical treatment or is
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also be used to debulk the lesion or improve cosmesis after invo-
lution. There can be signiﬁcant bleeding associated with resection
as IH are highly vascular lesions.
5. New treatment options: b-blocker therapy
5.1. Overview
There has been much excitement surrounding the treatment of
IH with b-blocker therapy. This treatment is quickly becoming ﬁrst
line treatment and was ﬁrst reported in 2008 by Léauté-Labrèze
et al, 29 who were caring for an infant with a large IH treated with
systemic corticosteroids. Steroid-induced cardiomyopathy required
the use of propranolol and within 24 hours of treatment a dramatic
reduction of the hemangiomawas noted. This serendipitous ﬁnding
has been substantiated by many studies demonstrating good
response to treatment of IH to b-blockade.30e42
The complete mechanism by which b-blockers work to treat
hemangiomas is unknown; however, it is accepted that b-blockade
interferes with endothelial cells, vascular tone, angiogenesis, and
apoptosis. The effect is in three stages: early, intermediate, and late,
each with different target actions.31 Blanching of the lesion occurs
during the early stage and is noted within 24 hours of treatment
initiation. This is secondary to vasoconstriction caused by the
release of nitric oxide. Intermediate effects are secondary to the
blockage of proangiogenic signals such as VEGF, basic ﬁbroblast
growth factor, and matrix metalloprotinease 2/9 and result in the
growth arrest of the hemangioma. Finally, in vitro studies have
shown that blockade of B adrenoreceptors by b-blockers results in
cellular apoptosis. This late stage apoptosis is another possible
mechanism by which b-blockers treat IH.
Propranolol, although not FDA approved for use in children, has
been used by pediatric cardiologists to treat cardiovascular mala-
dies for some time at doses up to 8 mg/kg/day in divided doses.30
This is a higher treatment dose than reported for the treatment of
IH and a 40-year review of propranolol toxicity in children found no
cases of mortality.34 The known side effects of propranolol includes
bronchospasm,34 hypoglycemia,35,36,43 mood disturbances, som-
nolence,44 bradycardia, and hypotension.34,35,37,44 All of these
adverse effects have been reported to resolve when the drug is
stopped or resolve spontaneously.
6. Systemic
Systemic treatment with propranolol is quickly becoming the
standard of care worldwide. It is considered for rapidly enlarging or
large IH that are vision or life threatening such as perioral hem-
angiomas causing feeding or breathing difﬁculty as well as orbital
hemangiomas causing ptosis, astigmatism, or orbital compartment
syndrome.
6.1. Treatment protocol
Many treatment protocols have been discussed in the litera-
ture.35,37 Some clinicians prefer to begin treatment and increase
dosing over days while admitted to the hospital to allow moni-
toring of vital signs in a controlled environment,35 whereas others
advocate initiation as an outpatient.38
Haider et al38 reported a protocol for outpatient treatment
evaluation starting with the baseline vital signs. If the hemangioma
is segmental or >5 cm, magnetic resonance imaging or magnetic
resonance angiography is performed of the head and neck to rule
out PHACES. If the hemangioma does not satisfy these re-
quirements, a baseline electrocardiogram is ordered. If abnormal,an echocardiogram and cardiac consultation is suggested. Once
PHACES is ruled out and the patient is cleared by cardiology,
treatment is initiated. The patient is started on 0.5 mg/kg/day
divided in three doses for 2e3 days. Every 2e3 days the dose in-
creases by 0.5 mg/kg/day until the ﬁnal treatment dose of 2.0 mg/
kg/day is reached. Blood pressure and pulse is taken 24 hours after
each dose increase.38
Propranolol dosages vary between studies and range between
1 mg/kg/day and 3 mg/kg/day. The most common dose reported is
2 mg/kg/day administered in divided doses and the treatment
duration reported has varied fromweeks to years. The treatment is
continued until the proliferative phase has ended or stabilization
has occurred.40 By natural history, proliferation of IH typically
continues until around 12 months of age. Similar to the higher
dose of propranolol noted in cardiology literature, adverse effects
have been noted including hypotension, fatigue, bronchospasm,
insomnia, and bradycardia.
Hypotension has been noted in cases where propranolol is used
for the treatment of periocular hemangiomas.34,35,37 Tan et al37
reported asymptomatic hypotension in a premature infant. The
propranolol was slowly increased over a 2-month period to 2 mg/
kg/day and the blood pressure normalized with no other inter-
vention. Low-dose propranolol administered in divided doses with
a gradual increase is advocated by Tan et al.37
At the end of treatment cardiac hypersensitivity has been re-
ported 1e2 days after discontinuing propranolol with a peak at 4e8
days and diminishing after 2 weeks.43 Tapering the dose over a 2-
week period has been reported to decrease the incidence of this
ﬁnding.35,38
7. Topical
More recently, topical application of b-blockers has been re-
ported to treat superﬁcial IH. Like propranolol, timolol maleate is a
nonselective b-blocker, and by the same proposed mechanism of
action as a topical medication, might be helpful in treating cuta-
neous capillary hemangiomas while having fewer systemic side
effects. Guo and Ni41 ﬁrst reported a case study demonstrating the
beneﬁt of topical 0.5% timolol solution applied topically twice
daily to a periocular IH. Since this report many studies have been
published demonstrating this positive response to topical
treatment.
Chambers et al43 reported the efﬁcacy of topical timolol maleate
gel 0.25% applied topically twice daily to non-vision-threatening
cutaneous infantile capillary hemangiomas. A retrospective,
consecutive, nonrandomized, comparative single-masked cohort
study of all patients presenting with non-vision-threatening peri-
ocular infantile capillary hemangiomas was performed. Parents
chose twice daily topical 0.25% timolol maleate gel or observation.
Lesions were clinically deﬁned as superﬁcial, mixed, or deep. The
primary outcome was response to treatment at 2 months, catego-
rized as good (size decreased >50%), moderate (decrease 0e50%),
or poor (enlarged or caused visually signiﬁcant ptosis or induced
astigmatism).
Thirteen children received timolol, and 10 children were
observed. In the treated group, good response was observed in
eight (61.5%) infants, moderate response was seen in four (30.8%)
infants, and poor response was seen in one (7.7%) patient. In the
observed group, none (0%) demonstrated good response, one (10%)
demonstrated moderate response, and nine demonstrated poor
response. Responses were consistent on long-term follow-up
(range, 3e41 months). Both superﬁcial (100% good response) and
mixed (43% good, 57%moderate) lesions responded well to timolol;
the one deep lesion did not. No adverse ocular or systemic effects
were observed.
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pears to be an effective way to treat periocular infantile capillary
hemangiomas that are non-vision-threatening at the time of pre-
sentation, and it can be considered as a treatment option for these
common lesions. Hemangiomas with a superﬁcial component can
be expected to respondwell, but enlarging deep lesions are likely to
require systemic treatment.43
In conclusion, IHs are common self-limiting tumors that can be
vision and life threatening. Since the report by Léauté-Labrèze
et al29 in 2008, b-blockers have been reported by numerous
studies to be an effective and exciting new treatment for IH. This
effect has been reported by both systemic and topical application.
There is a need for randomized control studies to further investi-
gate its effect and compare b-blocker therapy to previously
accepted treatments like steroids. The treatment is not without
adverse effects, yet may be safer than other treatment modalities
available. The workup protocol and treatment schemes must be
further investigated. b-blockade has shown much promise for the
treatment of IH and it may be the future treatment to care for this
common malady.References
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